A Bayesian phase I/II platform design for co‐developing drug combination therapies for multiple indications-Reference-Cited by-同舟云学术

A Bayesian phase I/II platform design for co‐developing drug combination therapies for multiple indications

Published:2021-11-03 Issue:2 Volume:41 Page:374-389
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

Mu Rongji¹^ORCID,Xu Jin²^ORCID,Tang Rui (Sammi)³^ORCID,Kopetz Scott⁴,Yuan Ying⁵^ORCID

Affiliation:

1. Clinical Research Center Shanghai Jiao Tong University School of Medicine Shanghai China

2. KLATASDS‐MOE, School of Statistics East China Normal University Shanghai China

3. Department of Biometrics Servier Pharmaceuticals Boston Massachusetts USA

4. Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

5. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA

Funder

National Cancer Institute

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.9242

Reference27 articles.

1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2. NCI.Common terminology criteria for adverse events (CTCAE) version 4.0. US Department of Health and Human Services. National Institutes of Health National Cancer Institute; 2009.

3. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials

4. The bivariate continual reassessment method

5. Dose-Finding Based on Efficacy-Toxicity Trade-Offs

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Bayesian pharmacokinetics integrated phase I–II design to optimize dose-schedule regimes;Biostatistics;2024-09-13

2. A Bayesian latent-subgroup platform design for dose optimization;Biometrics;2024-07-01

3. Dose Optimization for Novel Oncology Agents: Design Options and Strategies;Statistics in Biopharmaceutical Research;2024-02-26

4. A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints;Biometrics;2022-05-25